The company filed its registration statement with the U.S. Securities and Exchange Commission, but did not disclose the number of shares to be offered or how much the company hopes to raise by offering its common stock. Kythera submitted its registration statement to the Securities and Exchange Commission on a confidential basis under the Jumpstart Our Business Startups (JOBS) Act.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. will act as joint book-running managers for the offering. Leerink Swann LLC will act as lead co-manager and Lazard Capital Markets LLC will act as co-manager.
The company develops prescription products for the cosmetic medicine market. It is developing ATX-101, an injectable drug aimed at reducing submental fat, which leads to the appearance of a so-called “double chin.” The drug is currently in Phase III clinical development.